POM-V Prescription Required Companion Animal

Zodon 25 mg/ml Oral Solution for Cats and Dogs

Active ingredient: Clindamycin

Form

Liquid

Species

Cats Dogs

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5060

What it's used for

Cats: For the treatment of infected wounds and abscesses caused by clindamycin- susceptible species of Staphylococcus spp and Streptococcus spp. Dogs: • in...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clindamycin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Zodon 25 mg/ml Oral Solution for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Cats:
For the treatment of infected wounds and abscesses caused by clindamycin-
susceptible species of Staphylococcus spp and Streptococcus spp.
Dogs:
•
infections caused by or associated with clindamycin-sensitive species of
Staphylococcus spp, , ,
necrophorum, Clostridium perfringens
•
treatment of infections of the gingival and periodontal tissues
•Staphylococcus aureus

Revised: October 2025
AN: 01739/2025

For oral administration only
Recommended dose:
Cats:
Infected wounds, abscesses: 11mg of clindamycin per kg of body weight per 24h or
5.5 mg /kg per 12h for 7 to 10 days.
The treatment should be stopped if no therapeutic effect is observed after 4 days.

Revised: October 2025
AN: 01739/2025
Dogs:
- Infected wounds, abscesses and oral cavity/dental infections: 11 mg clindamycin
per kg of body weight per 24h or 5.5 mg /kg per 12h for 7 to 10 days.
The treatment should be stopped if no therapeutic effect is observed after 4 days.
- Treatment of bone infections (osteomyelitis): 11 mg clindamycin per kg of body
weight every 12 hours for a period of 28 days minimum. The treatment should
be discontinued if no therapeutic effect is observed in the first 14 days.
To ensure
administration
of a correct
dose, body
weight should
be determined as accurately as possible.
A 3 ml graduated syringe is provided to facilitate the administration of the veterinary
medicinal product.
The solution is flavoured. The solution can be administered directly into the mouth of
the animal or added to a small quantity of food.

Do not use in hamsters, guinea pigs, rabbits, chinchillas, horses or ruminants because
clindamycin ingestion by these species may cause severe gastrointestinal disorders.
Do not use in cases of hypersensitivity to either clindamycin or lincomycin, or to any of
the excipients

Vomiting and/or diarrhoea have been reported very rarely
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)

Revised: October 2025
AN: 01739/2025
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

None.

Special precautions for use in animals
Inappropriate use of the product may increase the prevalence of bacteria resistant to
clindamycin. Whenever possible, clindamycin should only be used based on
susceptibility testing including the D-zone test.
Official national and local antimicrobial policies should be taken into account when the
product is used.
Clindamycin is likely to favour the proliferation of non-susceptible organisms such as
resistant
corrective measures should be taken based on clinical observations.
Clindamycin shows parallel-resistance with lincomycin and co-resistance with
erythromycin. There is a partial cross-resistance to erythromycin and other macrolides.
In case of administration of high doses of clindamycin or during prolonged therapy of
one month or greater, tests for liver and renal functions and blood counts should be
performed periodically.
In dogs and cats with kidney problems and/or liver problems, accompanied by severe
metabolic aberrations, the dose to be administered should be carefully determined and
their condition should be monitored by performing appropriate blood tests during
treatment.
The use of the product is not recommended in neonates.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wash hands carefully after use.
People with known hypersensitivity to lincosamides (clindamycin and lincomycin)
should avoid contact with the veterinary medicinal product.
Care should be taken to avoid accidental ingestion as this may result in gastro-
intestinal effects such as abdominal pain and diarrhoea.
In case of accidental ingestion, particularly by a child, or allergic reaction seek medical
advice immediately and show the package leaflet or the label to the physician.

- Aluminium salts and hydroxides, kaolin and Aluminium-Magnesium-Silicate
complex may reduce the gastrointestinal absorption of lincosamides.
Products containing these substances should be administered at least 2
hours before clindamycin.
- Cyclosporin: clindamycin may reduce levels of this immunosuppressive drug
with a risk of lack of activity.
- Neuro-muscular blocking agents: Clindamycin possesses intrinsic
neuromuscular blocking activity and should be used cautiously with other
neuromuscular blocking agents (curares). Clindamycin may increase
neuromuscular blockade.
- Do not use clindamycin simultaneously with chloramphenicol or macrolides as
they both target the ribosome 50S subunit and antagonist effects may
develop.
- When using clindamycin and aminoglycosides (e.g. gentamicin)
simultaneously, the risk of adverse interactions (acute renal failure) cannot be
excluded.

Do not store above 30
o
C

Revised: October 2025
AN: 01739/2025

The treatment should be stopped if no therapeutic effect is observed after 4 days.

Revised: October 2025
AN: 01739/2025
Dogs:
- Infected wounds, abscesses and oral cavity/dental infections: 11 mg clindamycin
per kg of body weight per 24h or 5.5 mg /kg per 12h for 7 to 10 days.
The treatment should be stopped if no therapeutic effect is observed after 4 days.
- Treatment of bone infections (osteomyelitis): 11 mg clindamycin per kg of body
weight every 12 hours for a period of 28 days minimum. The treatment should
be discontinued if no therapeutic effect is observed in the first 14 days.
To ensure
administration
of a correct
dose, body
weight should
be determined as accurately as possible.
A 3 ml graduated syringe is provided to facilitate the administration of the veterinary
medicinal product.
The solution is flavoured. The solution can be administered directly into the mouth of
the animal or added to a small quantity of food.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No adverse effects have been reported in dogs after administration of high dosage up
to 300 mg/kg clindamycin.
Vomiting, loss of appetite, diarrhoea, leukocytosis and elevated liver enzymes have
been observed occasionally. In such cases, discontinue the treatment and administer
a symptomatic treatment.
4.11 Withdrawal period(s)
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.